STEM与日常科技·英语30篇（3）

3 / 30

mRNA平台与疫苗迭代速度

mRNA vaccines don’t contain live virus—they deliver genetic instructions for making just one harmless viral protein.
Once the platform is validated, swapping the mRNA sequence lets scientists build a new vaccine in weeks, not years.
During the Omicron surge, updated boosters entered clinical trials just 48 days after the variant’s genome was shared.
This speed relies on standardized lipid nanoparticles that safely carry any mRNA payload into human cells.
Manufacturing doesn’t require growing viruses in eggs or bioreactors, cutting both time and contamination risk.
Regulators now approve updates based on lab data alone—no need to repeat large-scale efficacy trials each time.
Future flu shots may refresh annually like software, matching circulating strains with precision and agility.
The platform’s flexibility makes it ideal not only for infectious disease but also for personalized cancer vaccines.